Leica Biosystems expanded a computational pathology collaboration with AstraZeneca and Daiichi Sankyo, building an end-to-end research workflow to quantify the TROP2 Normalized Membrane Ratio (NMR) biomarker in non-small cell lung cancer. The joint work uses AstraZeneca’s Quantitative Continuous Scoring (QCS) algorithm paired with Leica’s immunohistochemistry assay development, scanners, and image management tools. The collaboration delivers a reproducible workflow using Leica platforms including BOND RX and BOND-III stainers, Aperio GT 450 scanners, and the Aperio HALO AP image management system. Leica said the TROP2 NMR algorithm will be distributed via the Aperio AI Store as a research tool only. Separately, DiaDeep and Leica announced a commercial reseller partnership to bring DiaDeep’s oncology pathology AI applications into the Aperio AI Store, integrating within existing digital pathology workflows for pathologists. The deal underscores a push to make AI diagnostics more plug-and-play in routine labs.